Granules share price today

Granules India Ltd's share price was ₹794.60 at the close on 4 November 2026. It has been rising for 55 weeks. That is 5.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹544 and ₹909, and at that close it sat 69% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Granules India Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running.

Over the last 11 years the share price moved +648% while the NIFTY 500 moved +257%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: foreign funds (FIIs) raised their stake for 4 quarters in a row, indian funds and insurers (DIIs) cut their stake for 3 quarters in a row and revenue up on a year earlier for 6 quarters in a row.

1. Foreign funds (FIIs) raised their stake for 4 quarters in a row

   From 13.6% to 20.3% of the company by the September 2026 quarter.

2. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row

   From 18.5% to 15.3% of the company by the September 2026 quarter.

3. Revenue up on a year earlier for 6 quarters in a row

   In the June 2026 quarter revenue was ₹1,477 crore, +22.1% on a year earlier.

   Why: Revenue rose because the company sold more controlled substance medicines, mainly ADHD drugs in the US, where it gained share and launched products.

   Next results: check whether new amphetamine and methylphenidate products start adding sales and whether the company gets more quota.

   From the earnings call on 29 Sep 2026.

For April to June 2026 (the quarter ended 30 June 2026), Granules reported revenue of ₹1,477 crore, up 22.1% from ₹1,210 crore a year earlier, and a profit of ₹180 crore, up 59.3% from ₹113 crore.

Granules results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Granules' management discussed these results on a call held on 29 September 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Granules closed at ₹794.60 on 4 November 2026, up 43.3% from ₹554.65 a year earlier (7 November 2025) and up 147.2% over five years. Its highest weekly close since February 2016 was ₹909.30 on 11 September 2026.

Granules share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

566 weekly closes from 26 February 2016 to 4 November 2026.

4 Nov 2026: Granules closed at ₹794.60, down 5.4% on the week and down 3.3% on the month. 29 Sep 2026: Granules held its results call for April to June 2026. Management guided: Organic capital spending of about ₹2,000 crore over the next 3 to 4 years, weighted toward peptide CDMO, complex generics and oncology.

Earlier

• 30 Jul 2026: ex-date for a dividend of ₹1.75 a share.
• Results for April to June 2026: Revenue up 22.1% and profit up 59.3% on a year earlier.

Granules paid ₹1.75 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.22% at the ₹794.60 close on 4 November 2026. The last was a dividend of ₹1.75 a share, ex-date 30 July 2026.

Granules dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Granules India Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 29 September 2026, Granules' management guided: Organic capital spending of about ₹2,000 crore over the next 3 to 4 years, weighted toward peptide CDMO, complex generics and oncology.

“Our objective over the next 3 to 4 years is straightforward: to translate these investments into a substantially larger business, with earnings growing faster as our portfolio becomes more differentiated and operating leverage develops.”CMD, on the call for April to June 2026

What management guided

• Peptide CDMO to become profitable in FY27.
• Peptide CDMO annual revenue run rate of approximately $50 million in 3 years and at least $100 million in 5 years.
• R&D plan: 10-15 US submissions annually; 2 sole FTF ANDAs address more than $350 million, with potential 180-day exclusivity, and 4-5 further FTFs commercialize between FY30 and FY34.
• First US specialty and institutional product expected in FY29, with Canada B2C launching next year and meaningful Latin America and other international presence by FY30.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 29 September 2026.

When Granules reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Gagillapur FDA reinspection - check whether the expected inspection occurs and the site status advances.

Granules is on 3 of our India lists: Momentum stocks, Small & mid cap stocks and Pharma stocks.

Granules India Ltd earned ₹180 Cr of net profit in the Jun 2026 quarter, +59.3% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹595 Cr. Over 10 years profit has grown 17.1% a year on average. That is 12.2% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹113 Cr.

For the full year, FY26 profit was ₹595 Cr (+18.5% on the year before).

Why profit moved: revenue changed +22.1% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +38.6% and revenue +25.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Granules India Ltd reported ₹1,477 Cr of revenue in the Jun 2026 quarter, +22.1% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 14.7% a year on average. The last full year, FY26, came in at ₹5,366 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹5,633 Cr.

FY26 revenue was ₹5,366 Cr, +19.7% on the year before.

Recent pace: the last four quarters grew +25.3% on average, against 14.7% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +24.8%, against +9.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +38.1%, against +16.0% a year (accelerating).

Granules India Ltd's operating margin was 23.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 15.0% and 26.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +2.6 percentage points on the year while gross margin changed +0.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 140% of Granules India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹793 Cr of operating cash against ₹595 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹1,090 Cr of spending on assets, free cash was −₹297 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 140% of profit came in as cash: the cash cycle got 106 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 3.1× depreciation over three years. The next section checks what that spending is building.

Granules India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 256 days in FY26, up from 150 days in FY21. It spent ₹2,239 Cr on assets over the last 3 years. Customers take 62 days to pay, and stock sits for 326 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹5,366 Cr, each day of that cycle ties up about ₹14.7 Cr, so roughly ₹3,764 Cr is tied up in the business at any time.

FY26: customers took 62 days to pay and stock sat for 326 days, about 10.7 months of sales sitting as stock, for a full cycle of 256 days, longer than FY21's 150.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 326 days. Customers pay about 62 days after that. Suppliers are paid at 131 days. Together that makes the 256-day cycle.

Spending on assets: ₹2,239 Cr over the last 3 years, against ₹729 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹410 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Granules India Ltd's P/E is 33.3×, near the high end of its own history: higher than 97% of past readings. Its usual P/E (the middle reading) is 18.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹26.96.